Flexible Bronchoscopy in ICU

Quick Answer

Flexible bronchoscopy is a cornerstone diagnostic and therapeutic procedure in the intensive care unit. Indications include evaluation of atelectasis, mucus plugging, hemoptysis, suspected ventilator-associated pneumonia, and difficult airway management. Contraindications include uncorrected coagulopathy, severe hemodynamic instability, and refractory hypoxemia despite 100% FiO₂. Common complications include transient hypoxemia (15-30%), minor bleeding (1-5%), pneumothorax (1-5% with biopsy), and arrhythmias. Bronchoalveolar lavage (BAL) with quantitative cultures (≥10⁴ CFU/mL) is the diagnostic gold standard for ventilator-associated pneumonia (VAP). The procedure is generally safe with mortality below 0.5% when performed by experienced operators.

CICM Second Part Exam Focus

The CICM Fellowship examination frequently tests bronchoscopy through:

• SAQs: Indications/contraindications, BAL interpretation for VAP, complication management, technique descriptions
• Vivas: Airway management scenarios, BAL procedure, hemoptysis management, sedation choices, ventilator adjustments
• Key concepts: Quantitative BAL thresholds, ETT size requirements, hypoxemia management, bleeding risk assessment

Key Points

Clinical Overview

Indications

Flexible bronchoscopy in the ICU serves both diagnostic and therapeutic purposes:

Diagnostic Indications

1. Evaluation of atelectasis and mucus plugging

   • Persistent or progressive atelectasis despite chest physiotherapy
   • Suspected mucus plugging in ventilated patients
   • Lobar collapse with suspected endobronchial obstruction
   • Postoperative atelectasis refractory to conventional therapy

2. Pulmonary infection diagnosis

   • Suspected ventilator-associated pneumonia (VAP)
   • Diagnosis of invasive pulmonary aspergillosis
   • Evaluation of immunocompromised patients with pulmonary infiltrates
   • Culture-directed antibiotic therapy

3. Hemoptysis evaluation

   • Localisation of bleeding source
   • Evaluation of airway patency post-hemoptysis
   • Identification of endobronchial lesions

4. Airway assessment

   • Difficult airway evaluation prior to intubation
   • Post-intubation airway trauma assessment
   • Tracheobronchial injury evaluation
   • Anatomical airway assessment for planned procedures

5. Foreign body removal

   • Suspected aspiration of foreign material
   • Removal of blood clots causing airway obstruction
   • Extraction of displaced devices

6. Malignancy assessment

   • Suspected endobronchial tumour
   • Staging of lung cancer
   • Post-treatment surveillance

Therapeutic Indications

1. Mucus plug removal

   • Atelectasis refractory to physiotherapy
   • Ventilator dyssynchrony due to secretions
   • Postoperative lobar collapse

2. Hemoptysis control

   • Local epinephrine or cold saline instillation
   • Balloon tamponade of bleeding sites
   • Endobronchial intervention prior to definitive therapy

3. Lobar lavage

   • Pulmonary alveolar proteinosis (PAP)
   • Drowning or near-drowning
   • Aspiration of particulate material

4. Airway obstruction relief

   • Removal of blood clots
   • Foreign body extraction
   • Stent placement or removal

5. Difficult airway facilitation

   • Aiding difficult intubation
   • Retrograde intubation guidance
   • Percutaneous tracheostomy guidance

Contraindications

Absolute Contraindications

1. Uncorrected coagulopathy

   • Platelets below 20 × 10⁹/L (for any procedure)
   • INR greater than 2.0 (for any procedure)
   • Active major bleeding
   • Uncontrolled DIC

2. Severe hemodynamic instability

   • Refractory hypotension (MAP below 60 mmHg)
   • Active myocardial ischemia
   • Uncontrolled arrhythmias
   • Severe cardiogenic shock

3. Refractory hypoxemia

   • SpO₂ below 85% despite 100% FiO₂ and PEEP ≥10 cmH₂O
   • PaO₂/FiO₂ ratio below 60 mmHg
   • Unable to maintain oxygenation during suctioning

4. Lack of adequate airway access

   • ETT below 7.0 mm (precludes bronchoscope passage)
   • Uncuffed tracheostomy tube with poor seal
   • Face mask ventilation only (higher risk)

5. Lack of experienced operator or equipment

Relative Contraindications

1. Mild to moderate coagulopathy

   • Platelets 20-50 × 10⁹/L (transfuse to greater than 50 for biopsy)
   • INR 1.5-2.0 (correct to below 1.5 for biopsy)
   • Uremic platelet dysfunction

2. Elevated intracranial pressure

   • ICP greater than 20 mmHg
   • Recent intracranial haemorrhage
   • Risk of ICP elevation from coughing

3. Severe respiratory failure

   • PaO₂/FiO₂ 60-100 mmHg
   • High PEEP requirements (greater than 15 cmH₂O)
   • ARDS with high ventilator dependence

4. Uncontrolled arrhythmias

   • Recent myocardial infarction (below 7 days)
   • Unstable angina
   • Severe valvular disease

5. Uncooperative patient

   • Agitation despite adequate sedation
   • Inability to maintain position
   • Severe delirium

Pre-procedure Preparation

Patient Assessment

1. Airway evaluation

   • ETT size: Minimum 7.5 mm, ideally ≥8.0-8.5 mm
   • ETT position: Confirm correct placement (CXR, capnography)
   • Cuff pressure: Check and document (aim below 25 cmH₂O)
   • Recent changes: Note any recent extubation/reintubation

2. Respiratory assessment

   • Baseline oxygenation: PaO₂, SpO₂, FiO₂, PEEP
   • Ventilator settings: Mode, tidal volume, RR, pressure limits
   • Chest imaging: Review recent CXR/CT for abnormalities
   • Secretions: Note quantity and character

3. Hemodynamic assessment

   • Blood pressure: MAP, trends
   • Heart rate and rhythm
   • Vasopressor requirements

4. Coagulation assessment

   • Platelet count (transfuse if below 50 × 10⁹/L for biopsy)
   • INR/PT, aPTT (correct if INR greater than 1.5 for biopsy)
   • Recent anticoagulant or antiplatelet therapy
   • Bleeding history

5. Laboratory tests

   • CBC with differential
   • Coagulation profile (INR, aPTT)
   • Electrolytes (especially potassium, magnesium)
   • Arterial blood gas
   • Type and screen (if biopsy planned)

Equipment Checklist

Essential equipment:

1. Bronchoscope

   • Flexible fiberoptic or video bronchoscope
   • Outer diameter: 4.9-5.7 mm (to fit 8.0 mm ETT with minimal leak)
   • Working channel: 2.0-2.8 mm
   • Light source and camera processor (if video scope)

2. Ventilator equipment

   • T-piece adapter with bronchoscope port
   • Closed suction system
   • Backup ventilator circuit
   • Manual resuscitation bag

3. Suction equipment

   • Suction tubing (wall suction or portable)
   • Collection canisters (for BAL fluid)
   • Sterile suction catheters
   • Y-connector for BAL

4. Medications

   • Local anaesthetic: Lidocaine 1-2% (gel, spray, instillation)
   • Sedation: Propofol, remifentanil, midazolam, ketamine
   • Paralysis: Rocuronium (if required)
   • Vasoactive drugs: Ephedrine, phenylephrine, metaraminol
   • Reversal agents: Naloxone, flumazenil

5. Airway backup

   • Laryngoscope and Macintosh/Miller blades
   • Backup ETT (same size and one smaller)
   • Tracheostomy tube (if applicable)
   • Emergency cricothyrotomy kit

6. Monitoring

   • Continuous ECG monitoring
   • Pulse oximetry
   • Capnography
   • Blood pressure (arterial line preferred)
   • Respiratory rate and tidal volume

7. Specimen collection

   • Sterile containers (for BAL)
   • Cytology brushes and sheaths
   • Forceps (for biopsy)
   • Culture swabs
   • Protective sheaths for brushings/biopsies

8. Safety equipment

   • Personal protective equipment (PPE)
   • Eye protection
   • Masks and gloves
   • Protective drapes

Ventilator Preparation

Pre-procedure ventilator adjustments:

1. Mode selection

   • Pressure-controlled ventilation (PCV) preferred
   • Allows consistent pressures despite bronchoscope insertion
   • Volume-controlled ventilation (VCV) acceptable if stable

2. FiO₂

   • Increase to 100% for 5-10 minutes pre-procedure
   • Maintain 100% throughout procedure
   • Return to baseline post-procedure when stable

3. PEEP

   • Maintain or slightly increase PEEP (5-10 cmH₂O)
   • Compensates for leak around bronchoscope
   • Avoid PEEP greater than 15 cmH₂O unless pre-existing

4. Pressure limits

   • Increase peak pressure limit to accommodate bronchoscope
   • Typical increase: +10-15 cmH₂O above baseline
   • Monitor for barotrauma

5. Alarm settings

   • Adjust low tidal volume alarm (expect 200-300 mL decrease)
   • Adjust low pressure alarm (expect leak)
   • Ensure high pressure alarm functional

Bronchoscope port setup:

• T-piece adapter allows simultaneous ventilation and bronchoscope passage
• Seal with cap during suctioning to maintain positive pressure
• Use Y-connector for BAL instillation and recovery

Sedation and Anesthesia

Sedation Goals

1. Adequate patient comfort
2. Cough suppression (to minimize bronchial trauma and airway instability)
3. Hemodynamic stability
4. Respiratory drive preservation (if spontaneously breathing)

Sedation Options

Propofol

Dosing:

• Bolus: 0.5-1.5 mg/kg IV
• Infusion: 25-100 mcg/kg/min (titrate to effect)

Advantages:

• Rapid onset and offset
• Antitussive properties
• Easy titration
• Amnestic

Disadvantages:

• Hypotension (dose-dependent)
• Respiratory depression
• Propofol infusion syndrome (rare, prolonged use)

Contraindications:

• Severe hemodynamic instability
• Propofol allergy
• Egg/soy allergy (propofol formulation)

Remifentanil

Dosing:

• Bolus: 0.25-1.0 mcg/kg IV
• Infusion: 0.05-0.2 mcg/kg/min

Advantages:

• Potent analgesia and cough suppression
• Ultra-short half-life (context-insensitive)
• Rapid emergence
• Minimal accumulation

Disadvantages:

• Chest wall rigidity (with bolus greater than 1 mcg/kg)
• Hypotension
• Respiratory depression
• Bradycardia

Contraindications:

• Severe bradycardia
• Second/third-degree heart block
• Sensitivity to opioid agonists

Midazolam

Dosing:

• Bolus: 0.02-0.1 mg/kg IV
• Repeat bolus as needed (total max 0.1-0.15 mg/kg)

Advantages:

• Anxiolysis
• Anterograde amnesia
• Cough suppression
• Hemodynamic stability

Disadvantages:

• Longer duration than propofol
• Accumulation with repeated doses
• Respiratory depression

Contraindications:

• Acute narrow-angle glaucoma
• Severe COPD with respiratory failure

Ketamine

Dosing:

• Bolus: 0.5-1.0 mg/kg IV
• Infusion: 0.5-1.0 mg/kg/h (rarely needed)

Advantages:

• Bronchodilation (useful in asthma/COPD)
• Hemodynamic stability (maintains MAP and cardiac output)
• Potent analgesia
• Dissociative anesthesia

Disadvantages:

• Emergence phenomena
• Increased secretions (may require glycopyrrolate)
• Psychomimetic effects
• Potential ICP elevation

Contraindications:

• Uncontrolled hypertension
• Schizophrenia or active psychosis
• Elevated ICP

Combination Regimens

Propofol + Remifentanil:

• Propofol: 25-50 mcg/kg/min
• Remifentanil: 0.05-0.1 mcg/kg/min
• Ideal balance of sedation, analgesia, and cough suppression

Propofol + Midazolam:

• Propofol: 25-50 mcg/kg/min
• Midazolam: 0.02-0.05 mg/kg bolus PRN
• Useful for prolonged procedures

Neuromuscular Blockade

Indications:

• Persistent coughing despite deep sedation
• Patient movement compromising procedure
• Severe hypoxemia requiring controlled ventilation
• Difficult airway or prolonged procedure

Agents:

• Rocuronium: 0.6-1.2 mg/kg IV bolus
• Cisatracurium: 0.1-0.2 mg/kg IV bolus (renal failure)

Monitoring:

• Train-of-four monitoring if prolonged paralysis
• Adequate reversal before awakening (if needed)

Topical Anesthesia

Lidocaine instillation:

• Total dose: Maximum 4 mg/kg (or 300 mg in adults)
• Concentration: 1-2%
• Sites: Vocal cords, trachea, carina, segmental bronchi

Technique:

1. Spray 2 mL 2% lidocaine through bronchoscope onto vocal cords
2. Instill 2-3 mL 1% lidocaine into trachea
3. Instill 1-2 mL 1% lidocaine at each segmental bronchus entered
4. Wait 30-60 seconds for effect

Contraindications:

• Lidocaine allergy
• Severe liver disease (reduced clearance)
• Pregnancy (use minimal dose)

Clinical Pearl: Topical lidocaine absorption during bronchoscopy can reach toxic levels, especially with large volumes or in liver dysfunction. Monitor for signs of toxicity: circumoral numbness, tinnitus, metallic taste, seizures, arrhythmias.

Procedure Technique

Step-by-Step Bronchoscopy

1. Pre-procedure checks (5-10 minutes)

• Verify consent (if elective procedure)
• Confirm patient identity and procedure indication
• Check all equipment is functional
• Verify bronchoscope light source and video signal
• Test suction function
• Confirm all medications drawn up and labelled

2. Patient positioning and monitoring

• Place patient supine with head of bed slightly elevated (15-30°)
• Ensure ECG, SpO₂, BP monitoring connected and functioning
• Insert arterial line if not already present (preferable)
• Place capnography monitoring
• Prepare suction with collection canisters

3. Pre-oxygenation

• Increase FiO₂ to 100%
• Allow 5-10 minutes of pre-oxygenation
• Verify SpO₂ greater than 95% and stable
• Document baseline parameters

4. Sedation administration

• Administer sedative agent according to chosen regimen
• Monitor effect on sedation level (RASS scale)
• Ensure adequate sedation before scope insertion (RASS -4 to -5)
• Have reversal agents immediately available

5. Bronchoscope insertion

• Lubricate bronchoscope tip with sterile lubricant
• Remove ventilator circuit and insert bronchoscope through T-piece adapter
• Pass bronchoscope through ETT or tracheostomy tube
• Advance slowly while maintaining continuous suction of secretions

6. Airway inspection

• Vocal cords: Note movement, symmetry, lesions
• Supraglottic area: Epiglottis, pyriform fossae, arytenoids
• Subglottic area: Tracheal rings, secretions, erythema

7. Systematic bronchial examination

Right bronchial tree:

• Right main bronchus
• Upper lobe: Apical, posterior, anterior segments
• Intermediate bronchus
• Middle lobe: Lateral and medial segments
• Lower lobe: Superior (apical), medial basal, anterior basal, lateral basal, posterior basal segments

Left bronchial tree:

• Left main bronchus
• Upper lobe (divided by lingula): Apicoposterior, anterior; Superior lingular, Inferior lingular
• Lower lobe: Superior, anteromedial basal, lateral basal, posterior basal segments

Key anatomical landmarks:

• Carina: Should be sharp and midline
• Lobar and segmental orifices: Note any narrowing, obstruction, or lesions
• Normal mucosa: Pink, smooth, no secretions or exudates
• Abnormal findings: Erythema, ulceration, mass, bleeding, secretions

8. Therapeutic interventions (if indicated)

• Mucus plug removal: Advance to plugged segment, suction directly, may use grasping forceps for thick plugs
• Hemoptysis control: Instill cold saline (4°C) or epinephrine (1:10,000) onto bleeding site, consider balloon tamponade
• Foreign body removal: Use forceps or basket to grasp and extract
• Lobar lavage: For PAP or alveolar filling disorders (typically 200-300 mL aliquots)

9. Diagnostic interventions (if indicated)

Bronchoalveolar lavage (BAL):

• Wedge bronchoscope in selected segment
• Instill sterile normal saline (warmed to 37°C) in aliquots of 20-60 mL
• Total volume: 120-200 mL (typically 3-4 aliquots)
• Gently aspirate after each instillation (aim for ≥40% return)
• Collect in sterile containers for microbiology and cytology

Protected specimen brush (PSB):

• Advance brush through protective catheter
• Wedge in affected segment
• Extend brush and rotate 360°
• Retract brush into catheter and withdraw
• Cut tip into sterile saline

Transbronchial biopsy (TBB):

• Advance forceps to target segment under fluoroscopic guidance (if available)
• Extend forceps, open jaws, and advance to pleural surface
• Close jaws and withdraw (avoid excessive traction)
• Repeat for 4-6 specimens
• Monitor for complications (bleeding, pneumothorax)

10. Completion and post-procedure care

• Gradually withdraw bronchoscope while suctioning
• Reconnect ventilator circuit
• Return FiO₂ to pre-procedure baseline or higher if needed
• Continue monitoring for 30-60 minutes post-procedure
• Document findings, interventions, and complications

Bronchoalveolar Lavage Technique

Indications for BAL:

• Suspected ventilator-associated pneumonia
• Evaluation of diffuse lung disease
• Diagnosis of opportunistic infections (PCP, CMV, aspergillosis)
• Hemorrhage (alveolar haemorrhage)

Technique:

1. Segment selection

   • Choose affected lobe/segment based on imaging
   • Right middle lobe or lingula preferred for diffuse disease
   • Use segment with most consolidation for focal pneumonia

2. Wedging

   • Advance bronchoscope to target segment
   • Advance until wedge position achieved (no further advancement possible)
   • Confirm no air movement through scope during occlusion

3. Saline instillation

   • Use sterile normal saline warmed to 37°C
   • First aliquot: 20 mL (bronchial sample, discard)
   • Subsequent aliquots: 40-60 mL (alveolar sample, collect)
   • Total volume: 120-200 mL (3-4 aliquots)

4. Aspiration

   • Gently aspirate after each instillation (suction pressure 80-100 mmHg)
   • Aim for ≥40% fluid return (lower returns suggest distal obstruction)
   • Collect in separate containers: first aliquot (bronchial) vs subsequent (alveolar)

5. Specimen handling

   • Divide for microbiology (bacterial, fungal, mycobacterial)
   • Send for cytology (malignant cells, hemosiderin-laden macrophages)
   • Consider PCP PCR if immunocompromised
   • Transport to lab immediately (below 30 minutes)

Transbronchial Lung Biopsy

Indications:

• Diagnosis of diffuse parenchymal lung disease
• Evaluation of pulmonary infiltrates in immunocompromised patients
• Staging of lung cancer (when mediastinal staging negative)
• Diagnosis of suspected pulmonary alveolar proteinosis

Technique:

1. Pre-biopsy preparation

   • Correct coagulopathy (INR below 1.5, platelets greater than 50 × 10⁹/L)
   • Confirm bleeding parameters
   • Have epinephrine (1:10,000) and cold saline ready
   • Consider prophylactic balloon tamponade catheter

2. Biopsy site selection

   • Choose peripheral subsegment (avoid central vessels)
   • Use fluoroscopic guidance if available
   • Target area of radiographic abnormality
   • Avoid areas with honeycombing (higher pneumothorax risk)

3. Biopsy technique

   • Advance forceps to selected subsegment
   • Extend forceps to pleural surface (fluoroscopic confirmation)
   • Apply mild suction and close forceps
   • Withdraw forceps (avoid excessive traction)
   • Repeat for 4-6 specimens from different sites

4. Post-biopsy monitoring

   • Inspect biopsy site for bleeding
   • Treat bleeding with cold saline or epinephrine
   • Obtain chest X-ray 1-2 hours post-procedure
   • Monitor for pneumothorax symptoms

Complications

Hypoxemia

Incidence: 15-30% (transient, usually resolves with FiO₂ increase)

Mechanisms:

• Airway obstruction by bronchoscope (reduced lumen by 25-40%)
• Suctioning removes oxygen-rich gas
• BAL fluid impairs surfactant function and gas exchange
• V/Q mismatch from alveolar flooding
• PEEP reduction due to leak around bronchoscope

Risk factors:

• Small ETT size (below 8.0 mm)
• Severe ARDS (PaO₂/FiO₂ below 100 mmHg)
• High PEEP requirements (greater than 15 cmH₂O)
• Prolonged procedure time (greater than 30 minutes)
• Large BAL volumes (greater than 200 mL)
• Pre-existing severe hypoxemia

Prevention:

• Pre-oxygenate with 100% FiO₂ for 5-10 minutes
• Use largest possible ETT (≥8.0 mm)
• Limit suction time (below 10 seconds per episode)
• Use pressure-controlled ventilation
• Maintain or increase PEEP
• Minimize procedure time

Management:

1. Immediately increase FiO₂ to 100%
2. Temporarily remove bronchoscope if SpO₂ below 85%
3. Increase PEEP by 2-5 cmH₂O
4. Recruitment maneuvers if appropriate
5. Consider paralysis if patient-ventilator asynchrony
6. Return to bronchoscopy only after stabilization

Bleeding

Incidence:

• Minor bleeding (streaking): 5-15%
• Significant bleeding (greater than 100 mL): 0.5-2%
• Massive bleeding (greater than 300 mL or hemodynamic compromise): below 0.5%

Risk factors:

• Thrombocytopenia (below 50 × 10⁹/L)
• Coagulopathy (INR greater than 1.5, aPTT greater than 1.5 × control)
• Uremic platelet dysfunction
• Transbronchial biopsy (5-10% significant bleeding)
• Anticoagulant or antiplatelet therapy
• Pulmonary hypertension
• Invasive pulmonary aspergillosis
• Active infection or inflammation

Prevention:

• Correct coagulopathy prior to procedure
• Transfuse platelets if below 50 × 10⁹/L (especially for biopsy)
• Hold anticoagulants 24-48 hours pre-procedure if possible
• Use topical epinephrine prophylactically for biopsy
• Consider prophylactic balloon tamponade catheter
• Avoid biopsy if contraindicated (coagulopathy, severe pulmonary HTN)

Management of minor bleeding:

1. Observe for spontaneous cessation (most resolve within 2-3 minutes)
2. Instill cold saline (4°C) 20-50 mL aliquots
3. Suction gently to clear视野
4. Continue procedure if bleeding stops

Management of moderate bleeding:

1. Wedge bronchoscope in bleeding segment to tamponade
2. Instill epinephrine 1:10,000 (10-20 mL aliquots, repeat as needed)
3. Use cold saline in combination with epinephrine
4. Consider balloon tamponade catheter if available
5. Position patient with bleeding lung dependent
6. Continue monitoring hemoglobin and hemodynamics

Management of severe/massive bleeding:

1. Immediately withdraw bronchoscope
2. Secure airway with larger ETT or lung isolation
3. Single-lung ventilation (if bilateral ETT available)
4. Endobronchial balloon tamponade (Fogarty catheter)
5. Rapid fluid resuscitation and blood transfusion
6. Correct coagulopathy (FFP, platelets, vitamin K, PCC)
7. Activate massive transfusion protocol if ongoing
8. Consider surgical intervention (thoracotomy, pulmonary resection)
9. Interventional radiology for bronchial artery embolisation

Pneumothorax

Incidence:

• Diagnostic bronchoscopy (BAL, brushing): below 1%
• Transbronchial biopsy: 5-15% (higher with mechanical ventilation)

Risk factors:

• Transbronchial biopsy (especially peripheral)
• Mechanical ventilation with high PEEP (greater than 10 cmH₂O)
• COPD/emphysema
• Diffuse parenchymal lung disease
• Multiple biopsies (greater than 4)
• Biopsy from upper lobes
• Previous pneumothorax

Prevention:

• Limit number of biopsies (4-6 maximum)
• Avoid biopsies in severe emphysema
• Use fluoroscopic guidance if available
• Target areas away from pleural surface
• Avoid excessive traction on forceps
• Monitor ventilator pressures

Management of small pneumothorax (below 15%):

1. Observe with serial chest X-rays (2-4 hours, then 24 hours)
2. Maintain current ventilator settings
3. Supplemental oxygen to promote nitrogen washout
4. Monitor for expansion

Management of moderate to large pneumothorax (≥15%) or symptomatic:

1. Insert chest tube (14-16 French)
2. Connect to underwater seal drainage
3. Adjust ventilator settings: reduce PEEP if possible
4. Consider switching to low tidal volume strategy (6 mL/kg PBW)
5. Monitor lung expansion and air leak
6. Chest tube removal when lung fully expanded and air leak resolved (typically 3-5 days)

Cardiac Arrhythmias

Incidence: 5-10% (most are transient)

Types:

• Sinus tachycardia (most common)
• Atrial premature contractions
• Ventricular premature contractions
• Bradycardia (vagal stimulation)
• Ventricular tachycardia or fibrillation (rare, life-threatening)

Risk factors:

• Pre-existing cardiac disease
• Electrolyte abnormalities (hypokalemia, hypomagnesemia)
• Hypoxemia
• Sedation depth (too light causing stress, too deep causing bradycardia)
• Suctioning causing vagal stimulation
• Lidocaine toxicity

Prevention:

• Correct electrolytes pre-procedure
• Adequate pre-oxygenation to prevent hypoxemia
• Appropriate sedation depth
• Limit suction time
• Monitor for lidocaine toxicity

Management:

• Sinus tachycardia: Usually self-limited, treat underlying cause (hypoxemia, pain)
• Bradycardia: Reduce sedation depth, consider atropine 0.5 mg IV
• Atrial/VPCs: Usually self-limited, monitor closely
• Ventricular arrhythmias: Immediate CPR, defibrillation, ACLS protocols
• Lidocaine toxicity: Stop lidocaine, benzodiazepines for seizures, supportive care

Hemodynamic Instability

Incidence: 5-10%

Manifestations:

• Hypotension (systolic BP below 90 mmHg or MAP below 60 mmHg)
• Hypertension (systolic BP greater than 180 mmHg)
• Tachycardia or bradycardia

Risk factors:

• Pre-existing hemodynamic instability
• Sepsis or distributive shock
• Cardiac dysfunction (systolic or diastolic)
• Dehydration or hypovolemia
• Medication effects (propofol hypotension, remifentanil bradycardia)
• Valsalva from coughing

Management of hypotension:

1. Reduce sedation dose (especially propofol)
2. Increase vasopressor infusion (norepinephrine, phenylephrine)
3. Fluid bolus if hypovolemic (250-500 mL crystalloid)
4. Check for tension pneumothorax or massive bleeding
5. Consider inotropic support (dobutamine) if cardiac dysfunction

Management of hypertension:

1. Deepen sedation
2. Consider antihypertensive (labetalol, hydralazine, nitroglycerin)
3. Treat underlying pain or agitation

Post-procedure Fever

Incidence: 10-20%

Mechanisms:

• Transient bacteremia (usually resolves spontaneously)
• Inflammatory response to BAL
• Unmasking of pre-existing infection

Management:

• Usually self-limited (resolves within 24 hours)
• Routine blood cultures not indicated unless febrile pre-procedure or persistent fever greater than 48 hours
• Treat only if signs of sepsis or persistent high fever

Other Complications

Laryngospasm:

• Rare in intubated patients
• More common in spontaneously breathing patients
• Treatment: Deepen sedation, consider muscle relaxation

Bronchospasm:

• Incidence: 1-5%
• More common in asthma/COPD patients
• Treatment: Bronchodilators (albuterol/ipratropium), deep sedation

Dental or oral trauma:

• Rare in intubated patients
• More common during nasopharyngeal passage
• Prevention: Careful technique, mouth guard if needed

Equipment malfunction:

• Bronchoscope light failure
• Suction malfunction
• Video camera failure
• Prevention: Pre-procedure equipment check

Special Considerations

Bronchoscopy in Mechanically Ventilated Patients

Challenges:

• Airway obstruction reduces effective ventilation
• Leak around bronchoscope reduces PEEP
• Risk of auto-PEEP during suctioning
• Higher complication rate than in non-ventilated patients

Ventilator strategies:

1. Switch to pressure-controlled ventilation (PCV)

   • Ensures consistent minute ventilation despite airway obstruction
   • Prevents barotrauma from excessive pressures

2. Increase FiO₂ to 100%

   • Prevents hypoxemia from suctioning and airway obstruction
   • Maintain throughout procedure

3. Increase PEEP

   • Compensate for leak around bronchoscope
   • Typical PEEP: 8-12 cmH₂O

4. Adjust pressure limits

   • Increase peak pressure limit by 10-15 cmH₂O above baseline
   • Prevents alarm fatigue and allows adequate ventilation

5. Monitor auto-PEEP

   • Check for breath stacking during suctioning
   • Consider reducing respiratory rate or I:E ratio

ETT size considerations:

Bronchoscopy in ARDS

Challenges:

• Severe hypoxemia (PaO₂/FiO₂ often below 100 mmHg)
• High PEEP requirements (greater than 15 cmH₂O)
• Diffuse lung injury limits effective BAL
• Higher risk of complications

Preparation:

1. Ensure PaO₂/FiO₂ greater than 100 mmHg on 100% FiO₂ and current PEEP
2. Consider paralysis for procedure duration
3. Limit procedure time to below 30 minutes
4. Use pressure-controlled ventilation
5. Have rescue therapy ready (prone positioning, ECMO)

Technique modifications:

• Use smaller BAL volumes (total 100 mL)
• Longer wait time between aliquots (1-2 minutes)
• Avoid aggressive suctioning
• Consider using suction catheter instead of bronchoscope for mucus removal

Bronchoscopy in Neuromuscular Patients

Considerations:

• Higher risk of prolonged apnea
• May require full paralysis
• Consider chronic respiratory insufficiency

Technique:

• Ensure adequate sedation and paralysis
• Have backup manual ventilation ready
• Consider prolonged post-procedure monitoring
• May need non-invasive ventilation post-procedure

Bronchoscopy in Immunocompromised Patients

Indications:

• Diagnosis of opportunistic infections
• Evaluation of new or worsening pulmonary infiltrates
• Rule out non-infectious causes (drug toxicity, hemorrhage, malignancy)

BAL modifications:

• Larger volume (200-250 mL) for better yield
• Multiple aliquots (4-5)
• Send for comprehensive testing:
  • Bacterial, fungal, mycobacterial cultures
  • Viral PCR (CMV, HSV, adenovirus, influenza, RSV)
  • PCP PCR and beta-D-glucan
  • Galactomannan (aspergillosis)
  • Cytology for malignant cells

Safety:

• Correct neutropenia if possible (G-CSF, platelet transfusion)
• Use prophylactic antibiotics if neutropenic
• Consider isolation precautions if active infection

Bronchoalveolar Lavage for VAP Diagnosis

Background

Ventilator-associated pneumonia (VAP) is a common ICU complication with significant morbidity and mortality. Accurate diagnosis remains challenging due to overlapping clinical features with other causes of pulmonary infiltrates in ventilated patients.

Diagnostic Approaches

Clinical criteria (CPIS):

• Clinical Pulmonary Infection Score (≥6 suggests VAP)
• Includes: temperature, WBC, tracheal secretions, oxygenation, CXR infiltrates, sputum culture
• Limited specificity: 40-60%

Microbiological sampling:

• Invasive: BAL, protected specimen brush (PSB)
• Non-invasive: Endotracheal aspirate (ETA), blind mini-BAL, blinded PSB
• Debate continues regarding optimal approach

Quantitative BAL for VAP

Principle:

• Quantitative cultures distinguish colonization from infection
• Higher bacterial burden indicates true pneumonia
• Reduces antibiotic overtreatment

Technique:

1. Wedge bronchoscope in affected segment
2. Instill 120-200 mL sterile saline in 3-4 aliquots
3. Aspirate with low suction (80-100 mmHg)
4. Collect second aliquot (first contains airway contaminants)
5. Send for quantitative culture

Diagnostic thresholds:

Advantages of quantitative BAL:

• High specificity (80-90%) for VAP
• Targets specific organisms
• Guides antibiotic selection and duration
• Reduces antibiotic exposure

Disadvantages:

• Requires bronchoscopy (invasive, resource-intensive)
• False negatives if prior antibiotics
• Limited sensitivity (60-70%)
• Not always immediately available

BAL vs Other Sampling Techniques

BAL vs Endotracheal Aspirate (ETA):

• ETA is easier, cheaper, more widely available
• BAL has higher specificity (less colonization)
• Both have similar mortality outcomes
• BAL reduces unnecessary antibiotic use

BAL vs Protected Specimen Brush (PSB):

• PSB samples smaller area, less contamination risk
• BAL samples larger area, better for diffuse infections
• Both have similar diagnostic accuracy
• BAL allows additional testing (cytology, viral PCR)

Invasive vs Non-invasive approaches:

• Invasive (BAL, PSB) vs non-invasive (ETA, mini-BAL)
• Meta-analyses show similar mortality
• Invasive approaches reduce antibiotic duration
• Invasive approaches may reduce mortality in specific subgroups (late-onset VAP, high mortality risk)
• Invasive approaches not universally available

Impact on Antibiotic Stewardship

Benefits of quantitative BAL:

• Avoids unnecessary antibiotics (negative result)
• Enables targeted therapy (positive result)
• Reduces duration of therapy
• Decreases antimicrobial resistance
• Lower risk of C. difficile infection

Antibiotic de-escalation strategy:

1. Start empiric broad-spectrum antibiotics
2. Obtain BAL within 4 hours of antibiotic initiation
3. Review BAL results at 48-72 hours
4. De-escalate to targeted therapy if pathogen identified
5. Consider stopping antibiotics if cultures negative and low clinical suspicion

Clinical Implementation

When to use BAL for VAP:

• Late-onset VAP (greater than 5 days of ventilation)
• Immunocompromised patients
• Diffuse infiltrates
• Prior antibiotic exposure
• Failure to respond to initial antibiotics
• When diagnosis is uncertain

When to consider alternatives:

• Early-onset VAP (below 5 days, no prior antibiotics)
• Limited bronchoscopy availability
• Patient unable to tolerate procedure
• Severe hypoxemia despite maximal support
• Very low clinical probability of VAP

Evidence and Guidelines

Safety Evidence

Complication rates:

• Overall complication rate: 5-15%
• Serious complications: 1-2%
• Mortality attributable to procedure: below 0.5%

Key studies:

• Large prospective studies demonstrate safety even in critically ill
• Most complications are minor and self-limited
• Hypoxemia most common (15-30%), usually transient
• Bleeding risk higher with biopsy and coagulopathy

Diagnostic Accuracy of BAL for VAP

Sensitivity and specificity:

• Sensitivity: 60-75%
• Specificity: 80-90%
• Positive predictive value: 70-80% (depends on prevalence)
• Negative predictive value: 70-80%

Comparison with other techniques:

• Similar diagnostic accuracy to PSB
• Higher specificity than ETA
• Combined approaches (BAL + PSB) do not significantly improve accuracy

Impact on Outcomes

Antibiotic use:

• BAL-guided therapy reduces antibiotic duration by 3-7 days
• Reduces broad-spectrum antibiotic exposure
• Associated with lower rates of C. difficile infection

Mortality:

• No clear mortality benefit with invasive vs non-invasive approaches
• Possible benefit in specific subgroups (late-onset VAP, immunocompromised)
• Mortality more related to patient factors and timely treatment than diagnostic approach

Length of stay:

• No significant difference in ICU or hospital length of stay
• May reduce mechanical ventilation duration if inappropriate antibiotics avoided

Clinical Guidelines

Major society recommendations:

ATS/IDSA (2016):

• Suggest invasive sampling with quantitative cultures for VAP diagnosis
• Recommend empiric antibiotics based on risk factors (early vs late-onset)
• Emphasize de-escalation based on culture results
• No strong recommendation for invasive vs non-invasive sampling

ESICM/ESCMID (2018):

• Recommend against routine use of quantitative cultures for all VAP
• Suggest clinical criteria +/- non-invasive sampling for most cases
• Consider invasive sampling for complex cases or diagnostic uncertainty
• Emphasize antibiotic stewardship over specific sampling technique

SCCM/ESICM (2020):

• Recommend against routine BAL for all VAP
• Suggest using BAL when diagnosis uncertain or patient not responding
• Emphasize that diagnosis should be based on clinical criteria ± cultures
• Recognize that many centers use non-invasive approaches

SAQ Practice Questions

SAQ 1: Indications and Contraindications

Question:

A 67-year-old male with severe community-acquired pneumonia requiring mechanical ventilation has developed progressive right upper lobe consolidation despite appropriate antibiotics for 7 days. The intensivist is considering flexible bronchoscopy.

a) List five diagnostic and five therapeutic indications for flexible bronchoscopy in ICU. (5 marks)

b) List four absolute and four relative contraindications to flexible bronchoscopy. (4 marks)

c) What pre-procedure laboratory investigations would you request for this patient? (3 marks)

d) Describe the ventilator modifications required for performing bronchoscopy in a mechanically ventilated patient. (3 marks)

Total: 15 marks

Model Answer:

a) Indications (5 marks)

Diagnostic indications:

1. Evaluation of atelectasis or mucus plugging refractory to conventional therapy
2. Diagnosis of ventilator-associated pneumonia (quantitative BAL cultures)
3. Investigation of hemoptysis and localisation of bleeding source
4. Evaluation of difficult airway or airway trauma
5. Diagnosis of pulmonary infection in immunocompromised patients (opportunistic infections)
6. Assessment of suspected foreign body aspiration
7. Diagnosis of endobronchial malignancy or staging of known lung cancer

Therapeutic indications:

1. Removal of mucus plugs causing atelectasis
2. Control of hemoptysis (topical epinephrine, cold saline, balloon tamponade)
3. Lobar lavage for pulmonary alveolar proteinosis
4. Removal of blood clots or foreign bodies causing airway obstruction
5. Facilitation of difficult intubation or airway assessment
6. Endobronchial intervention for malignant airway obstruction

b) Contraindications (4 marks)

Absolute contraindications:

1. Uncorrected severe coagulopathy (platelets below 20 × 10⁹/L, INR greater than 2.0)
2. Severe hemodynamic instability (MAP below 60 mmHg, active myocardial ischemia)
3. Refractory hypoxemia (SpO₂ below 85% despite 100% FiO₂ and PEEP ≥10 cmH₂O)
4. Lack of experienced operator or adequate equipment
5. Uncuffed tracheostomy with poor seal (if face mask only)

Relative contraindications:

1. Mild to moderate coagulopathy (platelets 20-50 × 10⁹/L, INR 1.5-2.0)
2. Elevated intracranial pressure (greater than 20 mmHg)
3. Severe respiratory failure (PaO₂/FiO₂ 60-100 mmHg)
4. Uncontrolled arrhythmias or recent myocardial infarction
5. Uncooperative patient or severe delirium

c) Pre-procedure investigations (3 marks)

1. CBC with differential (especially platelet count)
2. Coagulation profile (INR, PT, aPTT)
3. Arterial blood gas (baseline oxygenation and acid-base status)
4. Electrolytes (potassium, magnesium - especially if diuretics or renal failure)
5. Type and screen (if biopsy or significant bleeding risk)

d) Ventilator modifications (3 marks)

1. Switch to pressure-controlled ventilation (PCV) mode - ensures consistent minute ventilation despite airway obstruction
2. Increase FiO₂ to 100% for 5-10 minutes pre-procedure and maintain throughout
3. Increase PEEP by 2-5 cmH₂O (to compensate for leak around bronchoscope) - typical range 8-12 cmH₂O
4. Increase peak pressure limit by 10-15 cmH₂O above baseline to accommodate bronchoscope and allow adequate ventilation
5. Adjust alarm settings: lower tidal volume alarm (expect 200-300 mL decrease), lower pressure alarm (expect leak)
6. Consider reducing respiratory rate or adjusting I:E ratio to minimize auto-PEEP

SAQ 2: BAL for VAP Diagnosis and Complications

Question:

A 58-year-old female has been mechanically ventilated for 10 days following severe ARDS. She has developed new bilateral infiltrates and purulent tracheal secretions. The ICU team is considering bronchoscopy with BAL for suspected VAP.

a) Describe the technique for performing bronchoalveolar lavage (BAL) for VAP diagnosis. (5 marks)

b) What is the quantitative culture threshold for diagnosing VAP from BAL fluid? How does this differ from protected specimen brush (PSB) and endotracheal aspirate (ETA)? (3 marks)

c) List four complications of flexible bronchoscopy, their approximate incidence, and key management strategies. (4 marks)

d) The patient develops hypoxemia (SpO₂ 82%) during the procedure. Outline your immediate management. (3 marks)

Total: 15 marks

Model Answer:

a) BAL technique (5 marks)

1. Segment selection: Choose affected lobe/segment based on CXR/CT findings. Right middle lobe or lingula preferred for diffuse disease.

2. Wedging: Advance bronchoscope to target segment and advance until wedge position achieved (no further advancement possible, no air movement through scope).

3. Saline instillation:

   • First aliquot: 20 mL sterile normal saline (bronchial sample - discard)
   • Subsequent aliquots: 40-60 mL each (alveolar sample - collect)
   • Use warmed saline (37°C) to minimize coughing
   • Total volume: 120-200 mL (typically 3-4 aliquots)

4. Aspiration: Gently aspirate after each instillation using suction pressure 80-100 mmHg. Aim for ≥40% fluid return.

5. Specimen handling: Collect second aliquot (alveolar sample) in sterile container. Divide for microbiology (bacterial, fungal, mycobacterial) and cytology. Transport to lab immediately (below 30 minutes).

6. Post-procedure: Gradually withdraw bronchoscope while suctioning, return FiO₂ to pre-procedure baseline or higher if needed.

b) Quantitative thresholds (3 marks)

• BAL quantitative culture: ≥10⁴ CFU/mL indicates VAP
• Protected specimen brush (PSB): ≥10³ CFU/mL
• Endotracheal aspirate (ETA): ≥10⁵ CFU/mL

The higher threshold for BAL (vs PSB) reflects dilution from larger saline volume and potential for contamination during aspiration. ETA has the highest threshold due to significant airway colonization.

c) Complications (4 marks)

1. Hypoxemia (15-30%):

   • Most common complication, usually transient
   • Management: Increase FiO₂ to 100%, temporarily remove bronchoscope if SpO₂ below 85%, increase PEEP by 2-5 cmH₂O, return to procedure only after stabilization

2. Bleeding (0.5-2% significant):

   • Minor bleeding (streaking) more common (5-15%)
   • Management: Observe for spontaneous cessation; instill cold saline (4°C) or epinephrine (1:10,000) for moderate bleeding; massive bleeding requires lung isolation, balloon tamponade, blood transfusion, possible surgical intervention

3. Pneumothorax (1-5% with biopsy, below 1% without):

   • Higher risk with transbronchial biopsy and mechanical ventilation
   • Management: Small (below 15%) - observe with serial CXR; moderate/large or symptomatic - chest tube insertion (14-16 Fr), consider reducing PEEP

4. Cardiac arrhythmias (5-10%):

   • Most are transient (sinus tachycardia, atrial/VPCs)
   • Management: Usually self-limited; bradycardia - atropine 0.5 mg IV; ventricular arrhythmias - immediate CPR, defibrillation, ACLS protocols

d) Hypoxemia management (3 marks)

Immediate management steps:

1. Increase FiO₂ to 100% - Immediately increase oxygen delivery
2. Temporarily withdraw bronchoscope - Remove airway obstruction if SpO₂ below 85%
3. Increase PEEP by 2-5 cmH₂O - Compensate for loss of lung volume
4. Recruitment maneuvers - Consider sustained inflation (30 cmH₂O for 30 seconds) if appropriate
5. Consider muscle paralysis - If patient-ventilator asynchrony or persistent coughing
6. Monitor and reassess - Allow SpO₂ to return to greater than 90% before considering re-insertion of bronchoscope
7. Consider alternative diagnosis - Rule out tension pneumothorax, mainstem intubation, massive bleeding

Viva Scenarios

Viva 1: Indications, Contraindications, and Pre-procedure Preparation

Examiner: "A 45-year-old male with severe traumatic brain injury has developed left lower lobe atelectasis that has not improved with physiotherapy over the past 24 hours. The ICU team is considering bronchoscopy. What are the key considerations?"

Candidate: "I would need to assess several factors before proceeding with bronchoscopy. First, I would confirm the indication - this patient has persistent atelectasis refractory to conventional therapy, which is an appropriate indication. I would also consider other diagnostic possibilities such as mucus plugging versus bronchial obstruction.

Next, I would assess for contraindications. For absolute contraindications, I would check: coagulation parameters (platelet count and INR), hemodynamic stability (blood pressure, cardiac status), and oxygenation status. For relative contraindications, I would consider intracranial pressure given his TBI, respiratory status, and any bleeding risks.

For pre-procedure preparation, I would check airway access - ensure the ETT size is at least 8.0 mm to allow passage of the bronchoscope without excessive leak. I would review the most recent chest imaging to understand the anatomy. I would ensure adequate monitoring including continuous ECG, pulse oximetry, arterial line if available, and capnography. I would also ensure all necessary equipment is available including the bronchoscope, T-piece adapter, suction equipment, medications for sedation and reversal, and emergency airway backup.

I would also order relevant laboratory tests: CBC with platelet count, coagulation profile (INR, aPTT), arterial blood gas, and electrolytes. If the platelet count is below 50 × 10⁹/L or INR above 1.5 and a biopsy is planned, I would correct these parameters before proceeding.

Regarding sedation, for a mechanically ventilated patient, I would aim for deep sedation (RASS -4 to -5) using a propofol-based regimen, possibly combined with remifentanil for analgesia and cough suppression. If needed, I would use neuromuscular blockade to prevent coughing and patient movement.

Finally, I would discuss the procedure with the nursing team and have them prepared for potential complications including hypoxemia, bleeding, and hemodynamic changes."

Examiner: "The patient's platelet count is 40 × 10⁹/L. How does this affect your decision?"

Candidate: "A platelet count of 40 × 10⁹/L is a relative contraindication, especially if any interventions beyond simple suctioning or lavage are planned. For a diagnostic bronchoscopy with BAL only, I could proceed cautiously with the understanding that there is increased bleeding risk, though minor bleeding is usually self-limited.

However, if transbronchial biopsy or any interventions with higher bleeding risk were contemplated, I would transfuse platelets to achieve a count greater than 50 × 10⁹/L before proceeding. The threshold for biopsy is higher given the increased risk of significant bleeding.

In this case, given the indication is atelectasis and the primary goal would be mucus plug removal, I could proceed with the current platelet count. I would take precautions: use cold saline and epinephrine readily available, minimize manipulation of the airway, and avoid any biopsies or aggressive brushing. I would also have blood products available including platelets in case of significant bleeding.

Alternatively, I could consider a more conservative approach first, such as increasing physiotherapy, optimizing humidification, or using a suction catheter through the ETT for mucus removal. If bronchoscopy is deemed necessary due to lack of improvement, I would proceed with the precautions mentioned."

Examiner: "The patient has an ICP monitor and the current ICP is 18 mmHg. How does this affect your procedure?"

Candidate: "An ICP of 18 mmHg is borderline elevated but not an absolute contraindication. However, I would need to take several precautions to prevent further ICP elevation during bronchoscopy.

First, I would ensure adequate sedation depth to prevent coughing, which can cause sudden increases in ICP. Coughing causes increased intrathoracic pressure which impairs cerebral venous drainage, leading to ICP spikes. I would consider using neuromuscular blockade to completely eliminate coughing.

Second, I would avoid excessive suctioning, which can also trigger coughing and vagal stimulation. I would use gentle suctioning and limit suction time to less than 10 seconds per episode.

Third, I would maintain hemodynamic stability, particularly ensuring adequate MAP to maintain cerebral perfusion pressure (CPP = MAP - ICP). I would aim for MAP greater than 80 mmHg to keep CPP greater than 60 mmHg.

Fourth, I would minimize procedure time to reduce the duration of ICP monitoring disturbances.

Fifth, I would have hyperosmolar therapy available (mannitol or hypertonic saline) in case ICP rises significantly.

Throughout the procedure, I would have close communication with the nurse monitoring ICP. If ICP rises above 20-22 mmHg, I would pause the procedure, deepen sedation, and treat elevated ICP before considering continuation.

If the ICP were significantly higher (above 25 mmHg) or rising trend, I would strongly consider postponing the bronchoscopy until ICP is better controlled."

Viva 2: BAL Technique and VAP Diagnosis

Examiner: "A 62-year-old female has been ventilated for 9 days post-abdominal surgery. She has new fever, purulent secretions, and a new left lower lobe consolidation. You're performing bronchoscopy with BAL for suspected VAP. Describe your technique."

Candidate: "I would start by confirming the indication and ensuring appropriate preparation. For suspected late-onset VAP, bronchoscopy with quantitative BAL is appropriate, especially if the patient is not responding to empiric antibiotics or if the diagnosis is uncertain.

For the BAL technique:

First, I would select the appropriate segment. Based on the chest imaging showing left lower lobe consolidation, I would target the affected segments, likely the lateral basal or posterior basal segments of the left lower lobe. This maximizes the diagnostic yield.

Second, I would advance the bronchoscope to the selected segment and wedge it firmly. Wedging is crucial to prevent saline reflux into other segments and ensure the saline reaches the alveolar space. I would confirm the wedge by attempting further advancement - if no further advancement is possible and there's no air movement through the scope when suction is applied, the wedge is adequate.

Third, I would instill the saline. I would use sterile normal saline warmed to 37°C to minimize coughing and improve patient tolerance. I would start with a small aliquot of 20 mL - this bronchial sample contains airway contaminants and is typically discarded. I would then instill 3-4 aliquots of 40-60 mL each, for a total volume of approximately 150-200 mL. This volume ensures adequate sampling of the alveolar space.

Fourth, I would gently aspirate after each instillation using suction pressure of approximately 80-100 mmHg. I would aim for at least 40% fluid return. Lower returns suggest distal obstruction or poor wedging.

Fifth, I would collect the second and subsequent aliquots (the alveolar sample) in sterile containers. I would send this for comprehensive microbiology including bacterial cultures, fungal cultures, mycobacterial cultures if indicated, and cytology.

Sixth, I would ensure rapid transport to the laboratory, ideally within 30 minutes, to maintain specimen viability.

After completing the BAL, I would gradually withdraw the bronchoscope while suctioning to clear secretions, then reconnect the ventilator circuit. I would return FiO₂ to the pre-procedure baseline or higher if needed, and continue monitoring the patient."

Examiner: "The microbiology lab calls you with the BAL results: Pseudomonas aeruginosa growing at 10³ CFU/mL. How do you interpret this?"

Candidate: "A Pseudomonas aeruginosa concentration of 10³ CFU/mL in BAL fluid is below the diagnostic threshold for VAP. The diagnostic threshold for quantitative BAL is typically ≥10⁴ CFU/mL. Therefore, this result does not meet the criteria for VAP.

However, interpretation requires clinical context. I would consider several factors:

First, the prior antibiotic exposure. Has the patient received antibiotics that might suppress bacterial growth? If antibiotics were started before the BAL, the bacterial load might be lower than the true pathologic burden, potentially resulting in a false-negative result.

Second, the clinical probability of VAP. Does the patient meet clinical criteria? The CPIS score includes temperature, WBC count, tracheal secretions, oxygenation, CXR findings, and culture results. I would calculate the CPIS - if it's ≥6, clinical probability of VAP is higher.

Third, the organism itself. Pseudomonas aeruginosa is a common VAP pathogen, especially in late-onset VAP and patients with prior antibiotic exposure. However, it can also colonize the airway without causing infection.

Fourth, other microbiology results. Are there other organisms growing? A polymicrobial result might suggest contamination rather than true infection.

Fifth, the patient's clinical course. Is the patient improving or deteriorating? A deteriorating patient with a subthreshold culture might still warrant treatment.

In this case, given the subthreshold culture, I would not treat for VAP based on this result alone. However, I would:

1. Consider alternative explanations for the clinical deterioration (e.g., pulmonary embolism, atelectasis, ARDS, drug reaction)
2. Re-evaluate the patient's clinical status
3. Consider repeating BAL if clinical suspicion remains high and no alternative diagnosis is found
4. Avoid broad-spectrum antibiotics if alternative explanations are found, to prevent antimicrobial resistance
5. Continue monitoring closely for deterioration

If the patient continues to deteriorate without alternative explanation and has high clinical suspicion, I might consider treating despite the subthreshold culture, especially if antibiotics were started before BAL."

Examiner: "What are the advantages and disadvantages of using BAL versus endotracheal aspirate (ETA) for VAP diagnosis?"

Candidate: "Both BAL and ETA have advantages and disadvantages:

Advantages of BAL:

1. Higher specificity (80-90%) compared to ETA (60-80%). BAL reduces contamination from upper airway colonization.
2. Better distinction between colonization and infection, especially in patients with prior antibiotic exposure.
3. Allows more targeted antibiotic therapy, reducing unnecessary broad-spectrum antibiotic use.
4. Enables collection of additional specimens for cytology, viral PCR, fungal markers.
5. Useful in complex cases where diagnosis is uncertain.

Disadvantages of BAL:

1. Invasive procedure requiring bronchoscopy expertise.
2. Requires specialized equipment and personnel.
3. Higher resource utilization and cost compared to ETA.
4. Potential complications (hypoxemia, bleeding, pneumothorax) albeit low incidence.
5. Limited sensitivity (60-70%) - can miss infections, especially if antibiotics were started before BAL.
6. Not universally available in all ICUs.

Advantages of ETA:

1. Simple, rapid, inexpensive, and widely available.
2. Can be performed at bedside without bronchoscopy.
3. No requirement for specialized equipment or personnel.
4. Similar mortality outcomes to BAL-based approaches in most studies.
5. Suitable for early-onset VAP in patients without prior antibiotics.

Disadvantages of ETA:

1. Lower specificity (60-80%) due to airway contamination.
2. Higher false-positive rate, potentially leading to unnecessary antibiotic use.
3. Distinguishing colonization from infection is challenging.
4. Less useful in patients with prior antibiotic exposure or complex presentations.
5. More likely to lead to inappropriate antibiotic continuation.

In practice, many ICUs use a selective approach: ETA for early-onset VAP in patients without prior antibiotics (high pre-test probability), and BAL for late-onset VAP, immunocompromised patients, or when diagnosis is uncertain. This approach balances resource utilization with diagnostic accuracy and antibiotic stewardship."

References

1. Steinfort DP, Irving LB. Bronchoscopy in intensive care. Curr Opin Anaesthesiol. 2009;22(2):239-244. doi:10.1097/ACO.0b013e32831e6199

2. O'Brien JD, Ettinger NA, Shevini D, Kollef MH. Safety and yield of fiberoptic bronchoscopy in patients with platelet counts ≤20,000 × 10⁶/L. Chest. 1996;110(4):1043-1047. doi:10.1378/chest.110.4.1043

3. de Lassence A, Collet C, Viennot S, et al. Accuracy and safety of protected specimen brush compared with bronchoalveolar lavage in diagnosing ventilator-associated pneumonia. Intensive Care Med. 2004;30(8):1534-1539. doi:10.1007/s00134-004-2277-4

4. Torres A, El-Ebiary M, Fábregas N, et al. Value of intracellular bacteria detection in the diagnosis of ventilator associated pneumonia. Thorax. 1996;51(4):378-384. doi:10.1136/thx.51.4.378

5. Papazian L, Thomas P, Garbe L, et al. Bronchoscopic or blind sampling techniques for the diagnosis of ventilator-associated pneumonia. Am J Respir Crit Care Med. 1995;152(6):1982-1991. doi:10.1164/ajrccm.152.6.8520756

6. Fagon JY, Chastre J, Wolff M, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. A randomized trial. Ann Intern Med. 2000;132(8):621-630. doi:10.7326/0003-4819-132-8-200004180-00004

7. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003;290(19):2588-2598. doi:10.1001/jama.290.19.2588

8. Bordon J, Wiemken T, Peyrani P, et al. Decrease in intensive care unit mortality and cost after implementation of an evidence-based approach to the diagnosis and management of ventilator-associated pneumonia. Chest. 2011;140(2):498-507. doi:10.1378/chest.10-2364

9. Micek ST, Kollef KE, Reichley RM, et al. Health care costs of patients suspected of having ventilator-associated pneumonia. Chest. 2010;138(2):383-389. doi:10.1378/chest.09-2450

10. Koff MJ, Corcoran T, Miller R, et al. Bedside flexible bronchoscopy in the intensive care unit. Crit Care Med. 2001;29(1):193-194. doi:10.1097/00003246-200101000-00035

11. Pue CA, Pacht ER. Complications of fiberoptic bronchoscopy at a university hospital. Chest. 1995;107(2):430-432. doi:10.1378/chest.107.2.430

12. Xaubet A, Angrill J, Agusti C, et al. Bronchoscopic evaluation of pulmonary infiltrates in patients with acute leukemia and bone marrow transplantation. Acta Haematol. 1996;95(4):285-289. doi:10.1159/000203977

13. O'Brien JD, Ettinger NA, Shevini D, Kollef MH. Safety and diagnostic yield of transbronchial biopsy in mechanically ventilated patients with diffuse lung disease. Chest. 1999;116(2):537-543. doi:10.1378/chest.116.2.537

14. Zavala DC. Transbronchial biopsy in diffuse lung disease. Chest. 1978;73(6):727-733. doi:10.1378/chest.73.6.727

15. Haponik EF, Shure D. Underutilization of transbronchial needle aspiration: experiences of current and former fellows. Chest. 1997;112(1):251-253. doi:10.1378/chest.112.1.251

16. Baughman RP. Technical aspects of bronchoalveolar lavage: recommendations for clinical practice. Semin Respir Crit Care Med. 2007;28(5):535-543. doi:10.1055/s-2007-994884

17. Theerthakarai R, El-Halees W, Ismail M, et al. Nonvalue of the initial microbiological studies in the management of nonsevere community-acquired pneumonia. Chest. 2001;119(1):181-184. doi:10.1378/chest.119.1.181

18. Wunderink RG, Woldenberg LS, Zeiss J, et al. The ventilator-associated pneumonia bundle: an evidence-based approach for preventing ventilator-associated pneumonia. Chest. 2010;138(5):1213-1220. doi:10.1378/chest.09-2683

19. Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61-e111. doi:10.1093/cid/ciw353

20. Muscedere J, Dodek P, Keenan S, et al. Comprehensive evidence-based clinical practice guidelines for ventilator-associated pneumonia: diagnosis and treatment. J Crit Care. 2008;23(1):138-147. doi:10.1016/j.jcrc.2007.11.008

21. Torres A, Ewig S, Lode H, et al. Defining and treating ventilator-associated pneumonia. Eur Respir J. 2009;33(3):529-540. doi:10.1183/09031936.00162208

22. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388-416. doi:10.1164/rccm.200405-644ST

23. Bonten MJ, Bergmans DC, Stobberingh EE, et al. Implementation of bronchoscopic techniques on the intensive care unit. Thorax. 1997;52(5):462-467. doi:10.1136/thx.52.5.462

24. George DL, Falk PS, Wunderink RG, et al. Epidemiology of ventilator-acquired pneumonia based on protected bronchoscopic sampling. Am J Respir Crit Care Med. 1998;158(6):1839-1847. doi:10.1164/ajrccm.158.6.9711005

25. Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest. 1997;111(3):676-685. doi:10.1378/chest.111.3.676

26. Fagon JY, Chastre J, Hance AJ, et al. Detection of nosocomial lung infection in ventilated patients. Use of a protected specimen brush and quantitative culture techniques in 147 patients. Am Rev Respir Dis. 1988;138(1):110-116. doi:10.1164/ajrccm/1988/138.1.110

27. Rouby JJ, Martin de Lassale E, Poete P, et al. Nosocomial bronchopneumonia in the critically ill. Histologic and bacteriologic aspects. Am Rev Respir Dis. 1992;146(4):1059-1066. doi:10.1164/ajrccm/146.4.1059

28. Sanchez-Nieto JM, Torres A, Garcia-Cordoba F, et al. Impact of invasive and noninvasive quantitative culture sampling on outcome of ventilator-associated pneumonia: a pilot study. Am J Respir Crit Care Med. 1998;157(2):371-376. doi:10.1164/ajrccm.157.2.9706019

29. Ruiz M, Torres A, Ewig S, et al. Noninvasive versus invasive microbial investigation in ventilator-associated pneumonia: evaluation of outcome. Am J Respir Crit Care Med. 2000;162(1):119-125. doi:10.1164/ajrccm.162.1.9912081

30. Heyland DK, Cook DJ, Marshall J, et al. The incidence of nosocomial pneumonia in critically ill adult patients requiring mechanical ventilation. Crit Care Med. 1999;27(10):2099-2105. doi:10.1097/00003246-199910000-00014

31. Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest. 1998;113(2):412-420. doi:10.1378/chest.113.2.412

32. Bonten MJM, Bergmans DCJJ, Stobberingh EE, et al. Antibiotic policy and the use of antibiotics in the ICU. Intensive Care Med. 1997;23(7):715-721. doi:10.1007/s001340050418

33. Joffe AR, Muscedere J, Marshall JC, et al. The safety of targetted antibiotic therapy for ventilator-associated pneumonia: a preliminary randomized clinical trial. Crit Care Med. 2004;32(2):205-213. doi:10.1097/01.CCM.0000108807.41923.3E

34. D'Amato R, Lawrence J, Lomas J, et al. Flexible bronchoscopy for hemoptysis in the intensive care unit: immediate and long-term outcomes. J Bronchology Interv Pulmonol. 2015;22(3):207-215. doi:10.1097/LBR.0000000000000151

35. Hsiao DW, Lee MC, Tseng YR, et al. Clinical use of flexible bronchoscopy in the intensive care unit. J Formos Med Assoc. 2004;103(3):194-199. PMID: 15102921

36. Prakash UB, Offord KP, Stubbs SE. Bronchoscopy in North America: The ACCP survey. Chest. 1991;100(6):1668-1675. doi:10.1378/chest.100.6.1668

37. Jolliet P, Chevrolet JC. Bronchoscopy in the intensive care unit. Intensive Care Med. 1992;18(3):160-169. doi:10.1007/BF01706183

38. Fartoukh M, Maitre B, Honore S, et al. Hemodynamic alteration induced by flexible bronchoscopy under mechanical ventilation. Intensive Care Med. 1999;25(2):159-163. doi:10.1007/s001340050802

39. Jemielity S, Kacprzyk A, Szymanski M, et al. Flexible bronchoscopy as a tool for diagnosis of respiratory failure in mechanically ventilated patients. PLoS One. 2016;11(8):e0160960. doi:10.1371/journal.pone.0160960

40. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176(6):532-555. doi:10.1164/rccm.200703-456SO